Rapport Therapeutics (NASDAQ:RAPP) Short Interest Update

21 Apr 2025, 18:16 by Teresa Graham · The Cerbat Gem

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,800,000 shares, an increase of 21.2% from the March 15th total of 2,310,000 shares. Approximately 16.1% of the shares of the company are short sold. Based on an average trading volume of 219,400 shares, the days-to-cover ratio is presently 12.8 days.

Analyst Ratings Changes

Several analysts recently issued reports on the company. JMP Securities assumed coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a “market outperform” rating and a $28.00 price target for the company. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a “mkt outperform” rating on the stock. Four research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.67.

Check Out Our Latest Research Report on Rapport Therapeutics

Rapport Therapeutics Trading Up 2.3 %

NASDAQ RAPP traded up $0.23 during midday trading on Monday, hitting $10.38. The company had a trading volume of 118,746 shares, compared to its average volume of 178,371. The company has a market capitalization of $378.83 million and a PE ratio of -0.75. Rapport Therapeutics has a twelve month low of $6.43 and a twelve month high of $29.74. The firm has a 50-day moving average price of $10.50 and a 200-day moving average price of $16.73.

Insider Buying and Selling at Rapport Therapeutics

In related news, Director Wendy B. Young bought 6,000 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average price of $10.21 per share, with a total value of $61,260.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $61,260. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Troy A. Ignelzi purchased 9,900 shares of the stock in a transaction on Wednesday, March 12th. The stock was bought at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the acquisition, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. TRV GP V LLC acquired a new position in Rapport Therapeutics during the fourth quarter valued at approximately $126,579,000. TRV GP VI LLC bought a new stake in shares of Rapport Therapeutics during the 4th quarter worth $17,194,000. Geode Capital Management LLC acquired a new stake in Rapport Therapeutics in the third quarter valued at about $4,133,000. Price T Rowe Associates Inc. MD grew its position in Rapport Therapeutics by 9.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after acquiring an additional 95,976 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Rapport Therapeutics in the fourth quarter worth about $1,105,000.

About Rapport Therapeutics

(Get Free Report)